Senolytics

Senescent cells stop dividing but do not die. They accumulate with age and secrete inflammatory proteins, a state called the senescence-associated secretory phenotype (SASP). Senolytics are drugs designed to selectively trigger apoptosis in these cells and clear them out.

The first published human trial of a senolytic combination, led by James Kirkland and Tamara Tchkonia's group at Mayo Clinic, gave 9 adults with diabetic kidney disease three days of oral dasatinib (100 mg/day) plus quercetin (1,000 mg/day). The pilot study found reduced markers of senescent cells in fat tissue and skin biopsies after treatment, the first evidence that a senolytic combination could reduce senescent cell burden in humans [1]. A separate registered trial, run at Mayo Clinic (NCT04313634), tested dasatinib, quercetin, and fisetin for skeletal health in older adults, reflecting the field's move toward larger, more rigorous designs [2].

What the evidence does not show: that senolytics reduce biological age in humans. A 2024 Phase I pilot study gave 19 participants six months of dasatinib plus quercetin and measured DNA methylation age directly, the actual epigenetic aging readout the field treats as a gold-standard proxy. The result ran opposite to the marketed narrative: epigenetic age acceleration significantly increased at 3 and 6 months on multiple clock algorithms, and telomere length notably decreased [3]. That is a real signal against, not for, the compound's anti-aging claim, in the exact outcome senolytics are supposed to improve. The trial was small (n=19, no placebo arm reported in this measure), so it does not prove senolytics accelerate aging either, but it directly undercuts the assumption, common in longevity marketing, that clearing senescent cells automatically lowers biological age.

No confirmed Blueprint page lists a specific senolytic protocol with a verified dose or schedule at the time of this review, so no self-experimentation claim from that program is attributed here.

Critics within the aging-biology field itself, not outside skeptics, are the ones raising the epigenetic-age finding. The pilot study's authors frame it explicitly as a call for caution, noting the effect on epigenetic clocks needs replication with a placebo arm before any conclusion about senolytics and biological aging can be drawn either way [3].

The honest takeaway: senolytics can measurably reduce senescent cell markers in small human studies over days, but the one trial that measured biological age over months found it moved in the wrong direction. This is an active, unsettled research area, not a proven anti-aging therapy.

Products with this: Quercetin, Fisetin